sub:assertion {
d:DB00241 dv:ddi-interactor-in dr:DB00241_DB01418 .
d:DB01418 dv:ddi-interactor-in dr:DB00241_DB01418 .
dr:DB00241_DB01418 dct:identifier "drugbank_resource:DB00241_DB01418" ;
dct:title "DDI between Butalbital and Acenocoumarol - Barbiturates such as butalbital may increase the metabolism of Vitamin K Antagonists such as acenocoumarol. Monitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Butalbital and Acenocoumarol - Barbiturates such as butalbital may increase the metabolism of Vitamin K Antagonists such as acenocoumarol. Monitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes. [drugbank_resource:DB00241_DB01418]"@en .
}